The Economic Times daily newspaper is available online now.

    Divis to spend Rs 300 crore on expansion plans in 2018

    Synopsis

    The company spent about Rs 400 crore till December last year and will be spending another Rs 300 crore on the expansion programme during the current year, L Kishore Babu chief financial officer said.

    divi's-laboratoryAgencies
    Divis which has four manufacturing facilities is engaged in manufacturing leading generic compounds, nutraceutical ingredients and custom synthesis of APIs and intermediates for global innovator companies.
    HYDERABAD: Drug firm Divis Laboratories is focussed on expanding capacities of existing plants, even as its proposed plant at Kakinada, Andhra Pradesh ran into rough weather, a senior official of the city-based drug maker said here today.

    The company spent about Rs 400 crore till December last year and will be spending another Rs 300 crore on the expansion programme during the current year, L Kishore Babu chief financial officer said.

    "Kakinada plant (in AP) may take some more time. The state government has to resolve the farmers issue. We will not undertake any work there until the farmers issue is resolved. So we are expanding the capacities of the existing plants," Kishore Babu told PTI here.

    "Capex for next year has not yet been decided. By March we will finalise it," he added.

    The state government allotted 505 acres of land at Ontimamidi Village (Kona), Thondangi Mandal, East Godavari District, and gave the company advance possession of the land, pending procedural formalities.

    The company has spent an amount of Rs 34.35 crore last year towards the cost of land and minor civil works at the site. The government has registered land of an extent of 351.72 acres in favour of the company, Divis said in its annual report of FY17.

    Several farmers whose land had been acquired or resumed by the government moved the High Court either contesting the acquisition or seeking higher compensation.

    Replying to a query, Kishore Babu said production at their Visakhapatnam plant has been normalised after the US FDA gave establishment inspection report (EIR) to the facility.

    "Production in the Vizag plant has been normalised," he added.

    Divis which has four manufacturing facilities is engaged in manufacturing leading generic compounds, nutraceutical ingredients and custom synthesis of APIs and intermediates for global innovator companies, the annual report said.


    (You can now subscribe to our Economic Times WhatsApp channel)
    (Catch all the Business News, Breaking News Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    ...more

    (You can now subscribe to our Economic Times WhatsApp channel)
    (Catch all the Business News, Breaking News Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    ...more
    The Economic Times

    Stories you might be interested in